Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China.
Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China.
Oral Oncol. 2019 Apr;91:7-12. doi: 10.1016/j.oraloncology.2019.01.012. Epub 2019 Feb 16.
Epstein-Barr virus (EBV)-positive cervical lymph node (CLN) metastasis of unknown primary origin is classified as nasopharyngeal carcinoma (NPC) T0 by the American Joint Committee on Cancer staging manual (8th edition). We aimed to investigate the possible primary sites and patterns of EBV-positive CLN metastases and to provide implications for the management of NPC T0 classification.
We retrospectively reviewed 269 patients with newly diagnosed EBV-positive CLN metastatic disease who underwent EBV detection via EBV-encoded RNA in situ hybridization. Fifteen patients with unknown primary tumors underwent follow-up after initial treatment.
In patients with EBV-positive CLNs, the most common primary sites after the nasopharynx (51.7%) were the salivary gland (24.5%), lung (7.8%), oropharynx (3.3%), nasal cavity/maxillary (3.3%), oral cavity (2.2%), orbit (1.1%), and liver (0.4%). No primary site was found in 15 patients (5.6%). For salivary gland malignancies, level II and I were the most frequently involved regions. Tumors arising from the lung or liver metastasized to the lower neck (level IV, V, and VI) rather than the upper neck. After initial treatment, 2/15 patients with EBV-positive CLNs of unknown primary exhibited primary NPC and oropharyngeal tumor, respectively. Further, even without prophylactic irradiation to the nasopharynx, only one of 13 unknown primary patients developed NPC.
The origins of EBV-positive CLNs may not be restricted to the nasopharynx alone, and are likely to involve the head and neck or non-head and neck regions. NPC T0 classification should be cautiously assigned to such tumors.
美国癌症联合委员会分期手册(第 8 版)将 EBV 阳性的颈淋巴结(CLN)转移且原发灶不明的病例归类为鼻咽癌(NPC)T0。本研究旨在探讨 EBV 阳性 CLN 转移的可能原发灶及模式,并为 NPC T0 分类的管理提供依据。
我们回顾性分析了 269 例新诊断为 EBV 阳性 CLN 转移的患者,这些患者均通过 EBV 编码 RNA 原位杂交检测 EBV。15 例原发灶不明的患者在初始治疗后进行了随访。
在 EBV 阳性 CLN 患者中,继鼻咽部(51.7%)之后最常见的原发部位是唾液腺(24.5%)、肺(7.8%)、口咽(3.3%)、鼻腔/上颌窦(3.3%)、口腔(2.2%)、眼眶(1.1%)和肝脏(0.4%)。15 例患者(5.6%)未发现原发灶。对于唾液腺恶性肿瘤,最常累及的区域是 II 区和 I 区。来源于肺或肝脏的肿瘤转移至下颈部(IV、V 和 VI 区)而非上颈部。在初始治疗后,2/15 例 EBV 阳性 CLN 原发灶不明的患者分别出现了鼻咽部和口咽部肿瘤。此外,即使没有对鼻咽部进行预防性放疗,13 例原发灶不明的患者中也仅有 1 例发生 NPC。
EBV 阳性 CLN 的起源可能不仅限于鼻咽部,还可能涉及头颈部或非头颈部区域。对于此类肿瘤,应谨慎地将 NPC T0 分类。